Filing Flows › Comparisons › ELUT vs FATE
Elutia vs Fate Therapeutics: ELUT and FATE compared
Elutia is the larger company: $2.4M of revenue in its latest quarter (Q2 2026) against $2.1M for Fate Therapeutics (Q2 2026). Fate Therapeutics is growing faster (+9% against -12% a year earlier).
Where the money goes: ELUT and FATE
Elutia (ELUT) · Q2 2026
Elutia, Q2 2026: revenue $2.4M (-12% year over year), operating margin -327.9%, net loss $7.6M, operating cash flow −$8.5M. The chart follows the revenue to costs, profit and cash.
Fate Therapeutics (FATE) · Q2 2026
Fate Therapeutics, Q2 2026: revenue $2.1M (+9% year over year), net loss $30.2M, operating cash flow −$23.4M. The chart follows the revenue to costs, profit and cash.
| Elutia (ELUT) | Fate Therapeutics (FATE) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $2.4M | $2.1M |
| Revenue growth, Y/Y | -12% | +9% |
| Operating margin | -327.9% | n/m |
| Net earnings | −$7.6M | −$30.2M |
| Net margin | -315.0% | — |
| Operating cash flow | −$8.5M | −$23.4M |
Questions
Which is bigger, Elutia or Fate Therapeutics?
Elutia is the larger company: $2.4M of revenue in its latest quarter (Q2 2026) against $2.1M for Fate Therapeutics (Q2 2026).
Is Elutia or Fate Therapeutics growing faster?
Fate Therapeutics is growing faster (+9% against -12% a year earlier).
More: Elutia earnings · how Elutia makes money · Fate Therapeutics earnings · how Fate Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.